Residual Exacerbations With Mepolizumab
Key facts
- Where
- Québec, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT04578171, who can take part
Where in Canada
- Institut universitaire de cardiologie et de pneumologie de QuébecQuébec, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Laval University
- Trial code
- NCT04578171
- Record updated
- 10 February 2025
- Original description
This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.Read full original descriptionShow less
Type and Mechanisms of Residual Asthma Exacerbations in Patients Treated With Mepolizumab
This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.
Inclusion: With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society; Eligible for mepolizumab treatment; Able and willing to sign the informed consent form.
Exclusion: Any respiratory disease apart from asthma; Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome.